Evaluation Of Liver Masses Research Articles

Contrast-Enhanced Imaging in the Management of Intrahepatic Cholangiocarcinoma: State of Art and Future Perspectives.

Intrahepatic cholangiocarcinoma (iCCA) represents the second most common liver cancer after hepatocellular carcinoma, accounting for 15% of primary liver neoplasms. Its incidence and mortality rate have been rising during the last years, and total new cases are expected to increase up to 10-fold during the next two or three decades. Considering iCCA's poor prognosis and rapid spread, early diagnosis is still a crucial issue and can be very challenging due to the heterogeneity of tumor presentation at imaging exams and the need to assess a correct differential diagnosis with other liver lesions. Abdominal contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) plays an irreplaceable role in the evaluation of liver masses. iCCA's most typical imaging patterns are well-described, but atypical features are not uncommon at both CT and MRI; on the other hand, contrast-enhanced ultrasound (CEUS) has shown a great diagnostic value, with the interesting advantage of lower costs and no renal toxicity, but there is still no agreement regarding the most accurate contrastographic patterns for iCCA detection. Besides diagnostic accuracy, all these imaging techniques play a pivotal role in the choice of the therapeutic approach and eligibility for surgery, and there is an increasing interest in the specific imaging features which can predict tumor behavior or histologic subtypes. Further prognostic information may also be provided by the extraction of quantitative data through radiomic analysis, creating prognostic multi-parametric models, including clinical and serological parameters. In this review, we aim to summarize the role of contrast-enhanced imaging in the diagnosis and management of iCCA, from the actual issues in the differential diagnosis of liver masses to the newest prognostic implications.

Evaluation of Liver Masses and Accompanying Findings by Diffusion-Weighted Magnetic Resonance Imaging

Evaluation of Liver Masses and Accompanying Findings by Diffusion-Weighted Magnetic Resonance Imaging

Evaluation of Liver masses with 16 Slice Multi-detector Computed Tomography with Pathological Correlation

Evaluation of Liver masses with 16 Slice Multi-detector Computed Tomography with Pathological Correlation

Early experience in the use of Levovist ultrasound contrast in the evaluation of liver masses

Australasian RadiologyVolume 44, Issue 3 p. 361-361 Early experience in the use of Levovist ultrasound contrast in the evaluation of liver masses J Plew, J Plew [Australis Radiol (2000) 44: 28-31]Search for more papers by this authorJ Sanki>, J Sanki> [Australis Radiol (2000) 44: 28-31]Search for more papers by this authorN Young, N Young [Australis Radiol (2000) 44: 28-31]Search for more papers by this authorS Gruenewald, S Gruenewald [Australis Radiol (2000) 44: 28-31]Search for more papers by this authorR Dwyer, R Dwyer [Australis Radiol (2000) 44: 28-31]Search for more papers by this authorR Brancatisano, R Brancatisano [Australis Radiol (2000) 44: 28-31]Search for more papers by this author J Plew, J Plew [Australis Radiol (2000) 44: 28-31]Search for more papers by this authorJ Sanki>, J Sanki> [Australis Radiol (2000) 44: 28-31]Search for more papers by this authorN Young, N Young [Australis Radiol (2000) 44: 28-31]Search for more papers by this authorS Gruenewald, S Gruenewald [Australis Radiol (2000) 44: 28-31]Search for more papers by this authorR Dwyer, R Dwyer [Australis Radiol (2000) 44: 28-31]Search for more papers by this authorR Brancatisano, R Brancatisano [Australis Radiol (2000) 44: 28-31]Search for more papers by this author First published: 09 October 2008 https://doi.org/10.1046/j.1440-1673.2000.044003361.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Volume44, Issue3August 2000Pages 361-361 RelatedInformation

Early experience in the use of Levovist ultrasound contrast in the evaluation of liver masses.

The aim of the present paper was to assess the utility of Levovist in defining the pathology of liver masses. Levovist is a new ultrasound contrast agent consisting of galactose microparticles, air bubbles and palmitic acid. Prospective studies were performed in patients referred for further evaluation of known liver masses. Levovist was peripherally injected and colour Doppler ultrasound studies were performed. Findings were correlated with clinicopathology and three other imaging modalities: biphasic spiral CT, CT arterial portography and contrast MRI. Twenty-five patients were studied (15 male and 10 female) in the age range 25-74 years. Liver masses ranged from 0.5 to 7 cm in maximum diameter. Thirteen lesions were benign and 12 were malignant (four hepatomas (HCC) and eight metastases). Levovist enhancement occurred in 18 lesions. Of these, six were benign (four focal nodular hyperplasias (FNH) and two haemangiomas). All 12 malignant lesions demonstrated enhancement. The HCC showed a mosaic pattern of central and peripheral enhancement, and the FNH demonstrated a spoke-wheel pattern. It was not possible to distinguish between haemangiomas and malignant lesions. Non-enhancing lesions may well be benign, with all malignancies showing some enhancement. Characteristic enhancement patterns were found for HCC (mosaic) and FNH (spoke-wheel). It was not possible to distinguish between metastases and benign lesions (haemangiomas) when the pattern of enhancement was peripheral.